Cargando…
Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deep...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532210/ https://www.ncbi.nlm.nih.gov/pubmed/26273206 http://dx.doi.org/10.2147/OTT.S87101 |
_version_ | 1782385197708214272 |
---|---|
author | Osumi, Hiroki Matsusaka, Satoshi Suenaga, Mitsukuni Shinozaki, Eiji Mizunuma, Nobuyuki |
author_facet | Osumi, Hiroki Matsusaka, Satoshi Suenaga, Mitsukuni Shinozaki, Eiji Mizunuma, Nobuyuki |
author_sort | Osumi, Hiroki |
collection | PubMed |
description | BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deepness of response (DpR) in patients treated with FOLFIRI plus C-mab. We aimed to evaluate the relationship between clinical outcome and DpR in metastatic colorectal cancer (mCRC) patients treated with second-line FOLFIRI plus C-mab. METHODS: A total of 112 patients with histopathologically confirmed mCRC treated with second-line FOLFIRI in combination with C-mab (N=42) or Bev (N=70) were retrospectively enrolled between October 2008 and June 2013. The relationship between DpR and clinical outcome in patients treated with FOLFIRI plus C-mab or Bev was determined. RESULTS: Forty-two patients treated with FOLFIRI plus C-mab had a mean DpR of 6.1% (inter-quartile range: −13.7%, 20.8%) and a minimum DpR of −62.7%. On the other hand, 70 patients treated with FOLFIRI plus Bev had a mean DpR of 0% (interquartile range: −16%, 10%) and a minimum DpR of −111%. DpR ≥30% was associated with significantly longer OS and PFS when compared with DpR ≤30% in patients given FOLFIRI plus C-mab. DpR (≥30%) was independently associated with prolongation of OS and PFS. In patients treated with FOLFIRI plus C-mab, there was a moderate positive correlation between DpR and clinical outcomes (OS: r=0.51, P<0.001; PFS: r=0.54, P<0.001). CONCLUSION: FOLFIRI plus C-mab yielded a stronger correlation between DpR and clinical outcomes. These results indicate the potential of DpR as a new measure of efficacy in mCRC patients treated with second-line chemotherapy plus C-mab. |
format | Online Article Text |
id | pubmed-4532210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45322102015-08-13 Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab Osumi, Hiroki Matsusaka, Satoshi Suenaga, Mitsukuni Shinozaki, Eiji Mizunuma, Nobuyuki Onco Targets Ther Original Research BACKGROUND: In the FIRE-3 trial, overall survival (OS) was significantly longer in patients treated with FOLFIRI plus cetuximab (C-mab) than in those treated with FOLFIRI plus bevacizumab (Bev), but progression-free survival (PFS) was not significantly different. This may be associated with the deepness of response (DpR) in patients treated with FOLFIRI plus C-mab. We aimed to evaluate the relationship between clinical outcome and DpR in metastatic colorectal cancer (mCRC) patients treated with second-line FOLFIRI plus C-mab. METHODS: A total of 112 patients with histopathologically confirmed mCRC treated with second-line FOLFIRI in combination with C-mab (N=42) or Bev (N=70) were retrospectively enrolled between October 2008 and June 2013. The relationship between DpR and clinical outcome in patients treated with FOLFIRI plus C-mab or Bev was determined. RESULTS: Forty-two patients treated with FOLFIRI plus C-mab had a mean DpR of 6.1% (inter-quartile range: −13.7%, 20.8%) and a minimum DpR of −62.7%. On the other hand, 70 patients treated with FOLFIRI plus Bev had a mean DpR of 0% (interquartile range: −16%, 10%) and a minimum DpR of −111%. DpR ≥30% was associated with significantly longer OS and PFS when compared with DpR ≤30% in patients given FOLFIRI plus C-mab. DpR (≥30%) was independently associated with prolongation of OS and PFS. In patients treated with FOLFIRI plus C-mab, there was a moderate positive correlation between DpR and clinical outcomes (OS: r=0.51, P<0.001; PFS: r=0.54, P<0.001). CONCLUSION: FOLFIRI plus C-mab yielded a stronger correlation between DpR and clinical outcomes. These results indicate the potential of DpR as a new measure of efficacy in mCRC patients treated with second-line chemotherapy plus C-mab. Dove Medical Press 2015-08-06 /pmc/articles/PMC4532210/ /pubmed/26273206 http://dx.doi.org/10.2147/OTT.S87101 Text en © 2015 Osumi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Osumi, Hiroki Matsusaka, Satoshi Suenaga, Mitsukuni Shinozaki, Eiji Mizunuma, Nobuyuki Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab |
title | Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab |
title_full | Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab |
title_fullStr | Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab |
title_full_unstemmed | Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab |
title_short | Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab |
title_sort | associations between deepness of response and clinical outcomes among japanese patients with metastatic colorectal cancer treated with second-line folfiri plus cetuximab |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532210/ https://www.ncbi.nlm.nih.gov/pubmed/26273206 http://dx.doi.org/10.2147/OTT.S87101 |
work_keys_str_mv | AT osumihiroki associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab AT matsusakasatoshi associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab AT suenagamitsukuni associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab AT shinozakieiji associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab AT mizunumanobuyuki associationsbetweendeepnessofresponseandclinicaloutcomesamongjapanesepatientswithmetastaticcolorectalcancertreatedwithsecondlinefolfiripluscetuximab |